Paclitaxel trevatide is under clinical development by AngioChem and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel trevatide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Paclitaxel trevatide overview

Paclitaxel trevatide (ANG-1005, GRN-1005) is under development for the treatment of leptomeningeal carcinomatosis (LC) from metastatic Her2-breast cancer, HER2 positive metastatic breast cancer, recurrent high-grade glioma, glioblastoma multiforme, anaplastic glioma, anaplastic astrocytoma, anaplastic oligodendroglioma and brain metastases. The drug candidate is administered as an intravenous infusion. It is a peptide-drug conjugate, containing the paclitaxel covalently linked to brain peptide vector, angiopep-2 in a 3:1 ratio. The drug candidate is developed based on an engineered peptide compound (EPiC) platform.

AngioChem overview

AngioChem is a clinical-stage biotechnology company. It discovers and develops new drugs to treat brain related disorders. The company offers products such as oncology products, peptide antibody conjugates, antibody-drug conjugates, pain products and lysosomal storage diseases products. It also offers ANG1005, ANG4043 and ANG2002. AngioChem develops small molecules and biologics for CNS diseases such as primary brain cancer, brain metastases, lysosomal storage diseases and pain. It’s technologies comprise beyond the blood-brain barrier and the LRP-1 solutions. Angiochem’s engineered drug compounds are used to cure array of brain diseases and brain related disorders. The company has research collaborations with government and academic research institutions. AngioChem is headquartered in Montreal, Quebec, Canada.

For a complete picture of Paclitaxel trevatide’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.